How to Optimize Cholesterol Management in High-Risk CV Patients

Slides:



Advertisements
Similar presentations
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Advertisements

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
NICE –CG 181 Continuum of CVD Risk and its treatment
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
European Society of Cardiology 2017 Clinical Trial Update I
AIM HIGH Niacin plus Statin to prevent vascular events
The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Neil J. Stone et al. JACC 2014;63:
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
TNT Study: Baseline Characteristics of the Patients
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
PCSK9 Inhibitors and Cardiovascular Outcomes
% decrease in LDL-C at 24 weeks from baseline
% decrease in LDL-C at 24 weeks from baseline
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
LDL Cholesterol.
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Elevated Admission Plasma Glucose Following ACS
Reducing Risk for CV Outcomes
Factor Xa Inhibitors in Coronary Artery Disease
DECLARE-TIMI 58.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Train-the-Trainer Cases
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Train-the-Trainer Cases
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Many post-MI patients are not receiving optimal therapy
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

How to Optimize Cholesterol Management in High-Risk CV Patients

Agenda

AHA/ACC Guidelines on the Management of Blood Cholesterol

AHA/ACC Guideline: Lifestyle Modification for ASCVD Risk Reduction

Secondary Prevention in Patients Not at High ASCVD Risk

Secondary Prevention in Patients at Very High ASCVD Risk

FOURIER: Cumulative Incidence of CV Events

AHA/ACC Guidelines Primary Prevention of ASCVD

Cost-Effectiveness of PCSK9 Inhibitors

EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

Stepwise, Incremental Therapeutic Strategy for Lipid Reduction in High-Risk Patients

Second STEMI and Residual Risk

Myocardial Infarction and Life Expectancy by Sex and Ethnicity

7-Year Risk of a Second MI Among 30-Day Survivors of First MI

Patient Case

Controlling Modifiable Risk Factors Is Essential in High-Risk ACS Patients

Addressing Residual Risk: Every MI Patient Should Be On a Statin (and Possibly Ezetimibe As Well)

FOURIER: Cumulative Incidence of Cardiovascular Events

Fourier: Results of an Exploratory Analysis in Patients with LDL-C <0.26 mM at Week 4

Safety Data From 5 Alirocumab Trials: No Safety Signal for Very Low LDL-C Levels

AHA Guidelines for Secondary ASCVD Prevention: Use of PCSK9 Inhibitors

Case Study in Secondary Prevention in a Patient With PAD, CAD, or Polyarterial Disease

Case Presentation: Patient Characteristics

How Should Therapy Be Advanced for This Patient?

Presence of Residual CV Risk in Large Prospective Studies of Optimal Statin Therapy

The TIMI Risk Score for Secondary Prevention

What Types of Events Is This Patient at Risk For?

How Should the Patient With Multiple Risk Factors Be Managed?

FOURIER: Cumulative Incidence of CV Events

Older Patients and Optimal LDL-C Reduction Therapy

Are There LDL-C Levels That Are Too Low?

Summary

Real Life Data With PCSK9 Inhibitors

Introduction/Overview

Majority of Very High-Risk Patients Not at LDL-C Level Target, < 70 mg/dL

EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients

LDL-C Reduction With PCSK9 Inhibitors: Real-World Data From a Regional Lipid Clinic

LDL-C Reduction From Baseline With PCSK9 Inhibitors at Various Doses

Observational Cohort Study: CV History at Baseline (N = 1186)

Median (Q1, Q3) LDL-C Reduction Following Evolocumab Initiation

Adverse Drug Reactions: Observational Cohort Study

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)